Gara Jalqabaatti › Diffuse Scleroderma › Illinois
Qorannoo klinikaalii Diffuse Scleroderma Illinois keessatti
Qorannoo 8 Diffuse Scleroderma f Illinois keessatti hirmaatuu jiru.
Magaalota Illinois keessatti
Takkalaa qorannoo (Ingiliffa)
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
- University of Chicago Hospitals, Chicago
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 hanga 70 · Saalaa hunda · Haaromfame 28-Ful-2026 · NCT06470048A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- The University of Chicago Medical Center, Chicago
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 hanga 74 · Saalaa hunda · Haaromfame 10-Ful-2026 · NCT07085104A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
- GSK Investigational Site, Chicago
Namoota walitti qabaa jiraSadarkaa 2/3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 08-Ful-2026 · NCT05878717A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- Northwestern Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 hanga 70 · Saalaa hunda · Haaromfame 28-Hag-2026 · NCT06925542Platform Clinical Study for Conquering Scleroderma
- The University of Chicago Medical Center (UCMC), Chicago
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 18-Hag-2026 · NCT06195072RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
- Northwestern Memorial Hospital, Chicago
- The University of Chicago Medical Center, Chicago
Namoota walitti qabaa jiraSadarkaa 2/3
Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 17-Hag-2026 · NCT06328777A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
- Nkarta Investigational Site, Chicago
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 07-Hag-2026 · NCT06733935AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
- Artiva Investigational Site Willowbrook, Willowbrook
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 31-Ado-2026 · NCT06991114Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.